# Evolva

produces fermentation-derived valencene at up to 94% purity, meeting EU flavor-ingredient regulation (EU 1334/2008) requirements for use in food and beverage applications.

Source: https://en.bioecon.ru/companies/evolva/
Updated: 2026-07-04

- Country: Switzerland

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | CHF 20 million initial purchase price plus up to CHF 10 million earn-out upon acquisition of Evolva AG by Danstar Ferment AG (Lallemand) in December 2023 | https://vegconomist.com/investments-finance/investments-acquisitions/lallemand-acquires-swiss-biotech-company-evolva/, https://www.bakingbusiness.com/articles/60642-lallemand-closes-deal-for-evolva-ag, https://www.eqs-news.com/news/corporate/evolva-and-lallemand-close-the-sale-of-evolva-ag-to-danstar-ferment-ag-on-28-december-2023/687d02d3-46a7-4ac1-80cb-09c52c3f7de3_en |
| Capacity | Expanded through third-party contract manufacturing organizations | https://evonextholdings.com/app/uploads/2020/05/20220310_Evolva_Annual_Report_2021.pdf, https://evonextholdings.com/app/uploads/2023/03/Evolva_Annual_Report_2022_finwebneu2.pdf |
| Certification | Meets EU Flavor-ingredient regulation (EU 1334/2008) requirements for valencene purity (minimum 94%) | https://evonextholdings.com/app/uploads/2020/05/20220310_Evolva_Annual_Report_2021.pdf, https://evonextholdings.com/app/uploads/2020/05/Evolva-HY-2021-Results_EN.pdf, https://evonextholdings.com/valencene/ |
| Regulatory approval | EU 1334/2008 regulatory compliance for valencene | https://evonextholdings.com/app/uploads/2020/05/20220310_Evolva_Annual_Report_2021.pdf, https://evonextholdings.com/app/uploads/2020/05/Evolva-HY-2021-Results_EN.pdf, https://evonextholdings.com/valencene/ |
| Headquarters | Reinach, Switzerland | https://evonextholdings.com/app/uploads/2020/05/2024-12-Evolva-Group-Annual-Report-2024.pdf, https://www.eqs-news.com/news/corporate/evolva-and-lallemand-close-the-sale-of-evolva-ag-to-danstar-ferment-ag-on-28-december-2023/687d02d3-46a7-4ac1-80cb-09c52c3f7de3_en |
| Headcount | 48 employees (at time of acquisition) | https://www.lallemand.com/lallemand-completes-acquisition-of-evolva/ |
| Revenue | CHF 6.4 million (total revenue, H1 2021); CHF 9.4 million (total revenue, 2023) | https://evonextholdings.com/app/uploads/2020/05/2024-12-Evolva-Group-Annual-Report-2024.pdf, https://evonextholdings.com/app/uploads/2020/05/Evolva-HY-2021-Results_EN.pdf |

Independent sources: bakingbusiness.com, eqs-news.com, evonextholdings.com, lallemand.com, vegconomist.com

## Technologies

- [Terpenes & terpenoids as platform molecules](https://en.bioecon.ru/technology/terpenes-terpenoids-platform-molecules/)